Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Astria Therapeutics, Inc. | a16-19428_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 4, 2016
Catabasis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
001-37467 |
|
26-3687168 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
|
One Kendall Square |
|
02139 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 349-1971
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 4, 2016, Catabasis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the completion of target enrollment for Part B of the Company’s MoveDMD clinical trial and the Company’s expectation that it will report top-line Phase 2 safety and efficacy results from the trial in the first half of the first quarter of 2017. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, and the information contained therein is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CATABASIS PHARMACEUTICALS, INC. | |
|
|
|
|
|
Date: October 4, 2016 |
By: |
/s/ Jill C. Milne |
|
|
|
|
|
|
|
Jill C. Milne |
|
|
|
President and Chief Executive Officer |